Author

Alison Goupil

Institution: Reaction Biology Corporation (United States)

Observed institutions: University of Dhaka, Reaction Biology Corporation (United States)

ORCID: 0000-0003-0024-3742

Observed ORCID: 0000-0003-0024-3742

OpenAlex ID: A5113149892

Comprehensive profiling of clinically approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposing

2026 · Mehlam Saifudeen, Songli Zhu, et al. · Nature Biotechnology · 10

Abstract 938: Screening the entire kinase-directed, FDA-approved pharmacopeia against the largest collection of wild-type and mutant kinases reveals many opportunities for drug repurposing and targeted therapy

2024 · Christian M. Loch, Shuguang Liang, et al. · Cancer Research · 1

Abstract 3305: Biochemical and cellular evaluation of HUNK inhibition by an FDA approved drug as potential therapeutic strategy for HER2+ breast cancer

2026 · Safnas Farwin AbdulSalam, Mia M. Eason, et al. · Cancer Research

Abstract 6489: Paradoxical activation of kinases occurs directly with ATP-competitive kinase inhibitors and is observable biochemically at physiologically relevant drug concentrations

2024 · Christian M. Loch, Mia Eason, et al. · Cancer Research

Copper-mediated regulation of CK2 kinase activity

2019 · Alison Goupil, Todd Strochlic, et al. · iDEA - Drexel University Institutional Repository

Works count: 5

Citation count: 11

H-index: 1

I10-index: 1